Related Experiment Video

Updated: Mar 25, 2026

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.9K

Belinostat for the treatment of relapsed or refractory peripheral T-cell lymphoma

Peter Campbell1, Christan M Thomas1,2

  • 11 Department of Pharmacy, NewYork-Presbyterian Hospital, University Hospital of Columbia and Cornell, New York, USA.

Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners
|February 28, 2016
PubMed

Insights

Belinostat offers a new treatment for relapsed or refractory peripheral T-cell lymphoma (PTCL), achieving a 25.8% response rate. This histone deacetylase inhibitor is well-tolerated and shows promise for patients with poor outcomes.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Peripheral T-cell lymphoma (PTCL) is a diverse non-Hodgkin lymphoma with historically poor prognoses.
  • Traditional chemotherapy offers limited efficacy and high relapse rates in PTCL patients.

Purpose of the Study:

  • To evaluate the efficacy and safety of belinostat for treating relapsed or refractory PTCL.
  • To assess belinostat's role as a histone deacetylase inhibitor (HDACi) in PTCL management.

Main Methods:

  • Clinical trial evaluating belinostat in patients with relapsed or refractory PTCL.
  • Assessment of overall response rate (ORR) and duration of response.
  • Monitoring of adverse reactions associated with belinostat treatment.

Main Results:

  • Belinostat demonstrated an overall response rate (ORR) of 25.8% in the evaluated patient cohort.
  • The median duration of response to belinostat was 8.4 months.
  • Common adverse reactions included nausea, vomiting, fatigue, pyrexia, and anemia.

Conclusions:

  • Belinostat is an approved and effective treatment option for relapsed or refractory PTCL.
  • The drug is generally well-tolerated, with a manageable safety profile.
  • Further investigations into belinostat's therapeutic applications in PTCL are ongoing.
Keywords:
Hematologylymphomaoncology

More Related Videos

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents14:04

Neutrophil Isolation and Analysis to Determine their Role in Lymphoma Cell Sensitivity to Therapeutic Agents

Published on: March 25, 2016

16.0K
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

28.0K

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

1.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.2K